|
Vaccines Manufacturing Technology and Services: Commercial Prospects 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
This report gives you the following benefits in particular: • You will receive hard data for the vaccines industry and market, including our revenue predictions for 2010-2025 • You will receive sales analyses for the overall vaccines market and its main components from 2010-2025, helping you to stay ahead • You will receive production forecasts for prominent regional sectors from 2010-2025 (North America, Switzerland, France, Germany, Belgium and Austria), including growth rates and market shares • You will discover prospects for the sector in general, as well as for contract vaccine manufacturing • You will gain insight into outsourcing for the vaccines sector, with revenue forecasts for contract manufacturing from 2010-2025 • You will discover how the overall sector will change and adapt from 2010-2025 • You will assess leading companies in vaccine manufacturing and contract vaccine manufacturing, discovering their activities and capabilities • You will discover the drivers, restraints, competition and opportunities influencing the sector from 2010 onwards • You will discover opportunities for established companies and new market entrants • You will receive expert views from our survey, including interview transcripts • You will find out where vaccines manufacturing is heading - technologically and commercially - from 2010 onwards. Our study gives you answers and trends - we aim to save you time and aid your decisions. 141 seiten | |||||||||||
| Inhalt der Studie: |
Our new report will show you how the industry and market for vaccines manufacturing will develop. You can indentify where the greatest opportunities will lie for human-use vaccines. There will be tren.....
Our new report will show you how the industry and market for vaccines manufacturing will develop. You can indentify where the greatest opportunities will lie for human-use vaccines. There will be trends to watch from 2010 onwards, with areas of revenue growth. You can have our report today, staying ahead. Which vaccines manufacturing segments will grow fastest from 2010? What are the commercial trends to watch? How will leading companies perform? We aim to save you time and benefit your work. Vaccine shortages during recent outbreaks - such as avian flu and swine flu - highlighted the shortcomings of some production methods and operations. Newer manufacturing systems are being developed, with manufacturers influenced by demand-side and regulatory needs. Our report covers the general and contract manufacturing sectors. Emerging processes can increase the yield of vaccine production, reduce time-to- market and improve cost efficiencies. We show you how the sector can harness those developments, predicting commercial results. Our report captures significant developments in vaccine manufacturing that are replacing traditional production methods. Vaccines Manufacturing Technology and Services: Commercial Prospects 2010-2025 analyses and discusses strengths, weaknesses and revenue trends of the sector from 2010 to 2025. This study provides data on the current and future of the vaccines market, covering sales and production capacity. We cover the overall world market and those of leading regions. Our report shows how you could benefit. Where will the best commercial opportunities lie? How will industry/market drivers and restraints affect the sector? We show you opportunities and challenges, with revenue trends for 2009 to 2025. There, you will discover commercial prospects at global, sub-market and regional levels. You can assess the potential of the vaccines manufacturing industry and market now. Industry and market analysis to save you time and aid your decisions Our new report examines the vaccines manufacturing technology and services sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, pipeline developments and other data. You can discover strengths, weaknesses, opportunities and threats in the sector. We include 59 tables and figures and two expert interviews - shown in the contents lists with this message. Report Highlights Companies Listed AAI Pharma Services Corp. A-Bio Pharma Pte Ltd. (A-Bio) Acambis ACE BioSciences ADImmune Advanced Bioscience Laboratories Advisory Committee on Immunization Practices (ACIP) Aeras Alfa Laval Alpha Biologics Althea Technologies Angel Biotechnology Holdings ANVISA Artelis Astellas AstraZeneca ATMI LifeSciences Avecia Biologics AVIR Green Hills Biotech Bavarian Nordic Baxter BioPharma Solutions Baxter International Beijing Hua-er-dun Biotech Co. (Hua-er-dun) Beijing Tiantan Biological Products Co. (BTBP) Bharat Biotech International Limited (BBIL) Bio Farma BioEos Biological E Bio-Manguinhos Biomay Biomed Biomedical Advanced Research and Development Authority (BARDA) BioNet-Asia Co. BioProperties Biovian Birmex Butantan Cadila Pharmaceuticals Cantacuzino Institute Catalent Pharma Solutions Cellexus Limited Central Research Institute Changchun BCHT Pharmaceutical Co. (BCHT) Changchun Changsheng Life Sciences (Changsheng) Changchun Institute of Biological Products (CIBP) Charles River Biopharmaceutical Services Chengdu Institute of Biological Products (CDIBP) China National Biotec Group Chiron Chongqing Jianchen Bioengineering Co. (Jiancheng) Chongqing Kangwei Biological Co. (Kangwei) Cobra Biomanufacturing Cognate Bioservices CPL Biologicals Crucell CSL Cytovance Biologics Daiichi-Sankyo Dale and Betty Bumpers Vaccine Research Center (VRC) Dalian Hissen Bio-pharm (Hissen) Dalian Jingang Andi Bio-products Co. (Andi) Dalian Jingang Biological Products Co. (Jingang) Defense Advanced Research Projects Agency (DARPA) Dendreon Department of Health and Human Services (HHS) Diosynth Biotechnology Dow Chemical Company DSM Biologics Dyosynth RTP Eden Biodesign European Medicines Agency (EMA) European Vaccine Manufacturers (EVM) Emergent BioSolutions Eurogentec Biologics EVI Finlay Institute Florida Biologix Food and Drug Administration (US FDA) Formatech Fraunhofer USA Center for Molecular Biotechnology (FhCMB) GAVI Alliance GE Healthcare Geovax GlaxoSmithKline (GSK) GlaxoSmithKline Biologicals Global Influenza Surveillance Network Goodwin Biotechnology Government Pharmaceutical Organisation (GPO) Green Cross Haiwang Interlong Halfkine Bio-Pharmac Harvard University Health Canada Henan Puxin Bio-engineering Co. (Puxin) Henogen HollisterStier Hospira Hualan Biological Engineering (Hualan) Human Biologicals Institute IAVI iBio IDT Biologika ImmunoCellular Therapeutics Indian Immunologicals Innogenetics Biologicals INSERM Instituto Fundaco Butantan Intercell Biomedical Intercell Corporation International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) JHP Pharmaceuticals Jiangsu Yanshen Biological Technology Co. (Yanshen) Jubilant Organosys Kaketsuken KBI Biopharma Korean FDA Kuhner Kunming Institute of Medical Biology (KIMB) Lanzhou Institute of Biological Products (LIBP) LG Life Sciences LigoCyte Pharmaceuticals Livzon Pharmaceutical Biotech Co. (Livzon) Lonza Medicago MedImmune MediVas Merck & Co. Meridian Bioscience Meridian Life Science Millipore Mitsubishi Tanabe Pharma Corporation Mogam Biotechnology Research Institute MSD Biologics Murdoch Childrens Research Institute (MCRI) Nabi Biopharmaceuticals Nanjing Dalu Dekang Biotech Co. (Dalu Dekang) National Heart Lung and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Vaccines and Biological Substances (IVAC) National Institutes of Health (NIH) National Vaccine & Serum Institute (NVSI) NCPC GeneTech Biotech Dev. Co. (GeneTech) Nobilon Northwest Biotherapeutics Novartis Novasep Novasep Process Novavax Omnia Biologics Onyvax OSO BioPharmaceuticals Manufacturing Oxford Biomedica Oxford University Oxford-Emergent Tuberculosis Consortium (OETC) PacificGMP Pall Life Sciences Pan American Health Organization (PAHO) Panacea Biotech Limited Paragon Bioservices PATH Pfenex Pfizer Vaccines PharmAthene Pharmedartis Phillip Morris International Pierre-Guérin Biolafitte ProBioGen Profectus Protein Sciences Corporation Queen Saovabha Memorial Institute Razi Vaccine and Serum Research Institute RecipharmCobra Biologics Richter-Helm BioLogics Sabin Vaccine Institute SAFC Pharma Sanofi Pasteur MSD Sanofi-Aventis Sartorius Stedium Scancell Schering Plough SCM Pharma Serum Institute of India Shanghai Fudan-Yueda Biotech Co. (Fudan-Yueda) Shanghai Institute of Biological Products (SIBP) Shanghai Institutes for Biological Sciences (SIBS) Shantha Biotechnics Shanxi Institute of Biological Products (SXIBP) Shenyang Baiao Biotech Co. (Baiao) Shenzhen Aokoo Biotechnologies (Aokoo) Shenzhen Kangtai Biological Products Co. (SKBP) Shenzhen Neptunus Interlong Biotech Co. (Interlong) Shenzhen Neptunus Interlong Bio-Technique Co. Sinovac Biotech Ltd. (Sinovac) Solvay Sumagen, Co. SynCo Bio Partners Takeda The Bill & Melinda Gates Foundation The Biovac Institute The Jenner Institute Thermo Scientific UNICEF University of Natural Resources and Applied Life Science University of Wisconsin-Madison US Centers for Disease Control and Prevention Vabiotech Vetter Pharma International VGXI Vibalogics Vical Vivalis Vivante GMP Solutions Waisman Clinical BioManufacturing Facility (WCBF) Wistar Institute Wockhardt World Health Organization (WHO) Wuhan Institute of Biological Products (WIBP) Wyeth (now part of Pfizer) Xcellerex Xiamen Innovax Biotech Co. Yunnan Wosen Biotechnology Co. (Wosen) Zhejiang Pukang Biotechnology Co. (Pukang) Zhejiang Tianyuan Bio-pharma Co. (Tianyuan) Zhejiang Tianyuan Bio-Pharmaceutical Co. Zydus Cadila [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Summary Points of this Report 1.2 Aims, Scope and Format of this Report 1.2.1 Chapter Outlines 1.3 Research and Analysis Methods 2. Introduction to Vaccines 2.1 Immunisation and Types of Vaccine 2.1.1 Vaccines: A Healthcare Triumph 2.1.2 The Immune System and Natural Immunity 2.1.3 Edward Jenner Laid the Foundation for Modern Vaccines 2.1.4 Vaccines Work by Creating Artificial Immunity 2.1.5 Vaccine Formulation 2.1.6 Types of Vaccine 2.1.7 Live, Attenuated Vaccines 2.1.8 Recombinant Live Vaccines 2.1.9 Inactivated Vaccines 2.1.10 Toxoid Vaccines 2.1.11 Subunit Vaccines 2.1.12 Conjugate Vaccines 2.1.13 Recombinant Subunit Vaccines 2.1.14 DNA Vaccines 2.1.15 Recombinant Vector Vaccines 2.2 Vaccine Preventable Diseases 2.2.1 Chickenpox and Shingles 2.2.2 Cholera 2.2.3 Diphtheria 2.2.4 Haemophilus Influenzae Type B (Hib) Diseases 2.2.5 Hepatitis A 2.2.6 Hepatitis B 2.2.7 Human Papillomavirus (HPV) - Cervical Cancer 2.2.8 Influenza 2.2.9 Seasonal Influenza 2.2.10 Pandemic Influenza 2.2.11 Influenza Vaccination 2.2.12 Japanese Encephalitis 2.2.13 Measles 2.2.14 Meningococcal Diseases (Neisseria Meningitidis) 2.2.15 Mumps 2.2.16 Pertussis 2.2.17 Polio 2.2.18 Rabies 2.2.19 Rotavirus Infections 2.2.20 Rubella 2.2.21 Streptococcus Pneumoniae Infections 2.2.22 Tetanus 2.2.23 Tick-Borne Encephalitis 2.2.24 Tuberculosis 2.2.25 Typhoid 2.2.26 Yellow Fever 3. The Global Vaccines Market, 2009-2025 3.1 Global Vaccines Market, 2009 3.1.1 Vaccine Types 3.1.2 Leading Vaccine Types 3.1.3 Leading Vaccine Brands 3.1.4 Leading Vaccine Manufacturers 3.2 Global Vaccine Market Forecast, 2010-2025 3.2.1 Opportunities in the Vaccines Market 3.2.2 The World Vaccine Market Will Double by 2015 3.2.3 The World Vaccine Market: Fastest- and Slowest-Growing Categories 3.3 Growth in Vaccine Market to Drive Efficiency in Vaccine Manufacturing 4. The Global Vaccines Manufacturing Market, 2009-2025 4.1 The Current State of Vaccines Manufacturing: The Supply Perspective 4.1.1 Conservative Nature: Market Slowly Opening to New Technology 4.1.2 Classification of Vaccine Manufacturers 4.1.3 Vaccine Manufacturing Market by Value, 2009: Dominated by A Few Global Manufacturers 4.1.4 Vaccine Manufacturing Market by Volume, 2009: A Contrasting Picture 4.2 Global Vaccine Production Forecast, 2010-2025 4.2.1 Vaccine Production Forecasting Method 4.2.2 Production Forecast for Vaccines, 2010-2020 4.2.3 Production Forecast for Vaccines, 2020-2025 4.3 Leading National Markets for Vaccine Manufacturing 4.3.1 Leading Vaccine Manufacturing Destinations, 2009 4.3.2 Vaccine Manufacturing: Regional Forecast, 2010-2025 4.3.3 Europe as the Manufacturing Hub of Global Vaccine Manufacturers 4.3.3.1 Vaccine Manufacturing Units of Top 10 Vaccine Manufacturers in European Countries 4.3.4 Vaccine Production in Developing Countries 4.3.4.1 Developing Countries as Leading Manufacturers for Specific Vaccine Types 4.3.4.2 Promoting Vaccine Production in Developing Countries 4.3.4.3 Factors Driving the Shift towards Developing Countries 5. Contract Manufacturing in the Global Vaccines Sector, 2009-2025 5.1 The Challenges in Outsourcing 5.2 Contract Manufacturing Market for Vaccines, 2009-2025 5.2.1 Market Size for Contract Manufacturing of Vaccines, 2009 5.2.2 Market Forecast, 2010-2025: Witnessing Growth Parallel to the Vaccines Market 5.3 Outsourced Activities 5.4 Changes in the Vaccine Market to Drive Contract Manufacturing 5.5 Prominent Contract Manufacturers with Vaccine Production Capabilities 5.5.1 SynCo Bio Partners B.V. 5.5.1.1 Overview 5.5.1.2 Facilities and Equipment 5.5.1.3 Capabilities 5.5.1.4 Focus on Vaccines 5.5.2 Baxter BioPharma Solutions 5.5.2.1 Overview 5.5.2.2 Facilities 5.5.2.3 Capabilities 5.5.2.4 Future Outlook 5.5.3 Meridian Life Science, Inc. 5.5.3.1 Overview 5.5.3.2 Facilities 5.5.3.3 Capabilities 5.5.3.4 Focus on Vaccines 5.5.3.5 Revenues 5.5.3.6 Future Outlook 6. Vaccine Manufacturing: Processes and Developments from 2010 6.1 Steps Involved in Vaccine Production 6.1.1 Egg-Based Manufacturing for Viral Vaccines: Traditional Technology 6.2 Development in Vaccine Manufacturing: Novel Technologies Reaching the Market 6.3 New Substrates for Vaccine Production 6.3.1 Egg-Based Manufacturing to Cell-Based Manufacturing Technology 6.3.2 Cell-Based Techniques have Advantages over Egg-Based Vaccine Production 6.3.3 Mammalian Cell Lines 6.3.3.1 MCDK (Madin Darby Canine Kidney Cells) 6.3.3.2 Vero Cells 6.3.3.3 Per C6 Cells 6.3.4 Avian-Derived Cell Lines 6.3.4.1 EB66 Stem Cell Technology: Vivalis 6.3.4.2 AGE1.CR: A Patent-Protected Duck Cell Line Developed by ProBioGen AG 6.3.5 Plant-Based Vaccines 6.3.5.1 Medicago's Proficia VLP Vaccine Technology 6.3.5.2 iBioLaunch Vaccine Technology: Plant-Based Production Platform from iBio 6.3.6 Insect Egg Based Production Systems 6.3.6.1 Novavax 6.3.6.2 Protein Sciences Corporation (PSC) 6.4 Next-Generation Expression Systems and Vectors: Increasing Production Yield 6.4.1 AdVac Technology: Crucell 6.4.2 AdCEV Vectors: AfriVax 6.4.3 Pfenex Expression Technology: Pfenex (A part of Dow Chemical Company before December 2009) 6.5 Increasing Use of Disposables/ Single-Use Systems 7. SWOT Analysis for Vaccines Manufacturing 7.1 Principal Strengths 7.1.1 Vaccines as Important Agents for Disease Control 7.1.2 New Vaccine Technologies 7.1.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines 7.1.2.2 New Types of Vaccine 7.1.2.3 New Adjuvants for Vaccines 7.1.2.4 New Vaccine Delivery Mechanisms and Formulations 7.1.2.5 Other Developments in Vaccine Technology 7.1.3 New High-Margin Vaccines 7.1.4 Vaccines Will Not Face Significant Generic Competition 7.1.5 Personalised Vaccines 7.2 Weakness 7.2.1 Difficult to Forecast Demand for Vaccines 7.2.2 High Costs and Complex Manufacturing Processes 7.2.3 Unknown Viral Strains 7.2.4 Limitations of the Production Facility: Difficult to Change Over to Different Product 7.3 Opportunities for Vaccine Manufacturers and Manufacturing Countries 7.3.1 China, India and Brazil Will Become Hubs for Manufacturing Paediatric Vaccines 7.3.2 Vaccines for Diseases Currently Without a Vaccine 7.3.3 Biodefence 7.3.3.1 The Future for Bioterrorism Vaccines 7.3.4 Pandemic-Preparedness 7.3.5 Changing World Demographics 7.3.5.1 Population Increase 7.3.5.2 Emerging-Market Economies 7.4 Threats 7.4.1 Consolidation Among Vaccine Manufacturers 7.4.2 Vaccines in the Developing World 7.4.2.1 Vaccine Distribution Networks 7.4.2.2 Vaccine Costs in Developing Countries 8. Expert Opinions 8.1 Mr. Patrick Lucy, Vice President, Business Development, Pfenex Inc. 8.1.1 About the Pfenex Technology 8.1.2 On Pfenex' Service Offerings 8.1.3 On Current State of Vaccine Manufacturing 8.1.4 On Novel Platforms Driving Vaccines Market 8.2 Dr Roger Lias, President & Group Commercial Director, Eden Biodesign, Inc. 8.2.1 On The Contract Manufacturing Market 8.2.2 On Future Growth Prospects of Vaccines Contract Manufacturing 8.2.3 About Eden Biodesign and its Capabilities 8.2.4 Industry Drivers 9. Conclusions 9.1 The Vaccines Market Can Experience Strong Growth from 2010 to 2025 9.2 Drivers for Change in Vaccines Manufacturing 9.3 Comparison of Vaccine Manufacturing Capabilities 9.4 Concluding Thoughts [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Vaccine-Preventable Diseases: Statistics from Recent Years Table 2.2 Influenza Virus Types Table 3.1 Definition of Vaccine Types Used in this Report Table 3.2 Vaccine Sales ($bn) and Shares (%) by Type, 2009 Table 3.3 Vaccine Sales ($bn) and Shares (%) by Brand, 2009 Table 3.4 Vaccine Sales ($m) and Shares (%) by Manufacturer, 2009 Table 3.5 Global Vaccine Market Forecast ($bn), 2010-2025 Table 3.6 Global Vaccine Market Forecast by Vaccine Type ($bn), 2010-2025 Table 4.1 Global Vaccine Production (bn doses), 2009 Table 4.2 Global Vaccine Production (bn doses): Forecast, 2009-2020 Table 4.3 Global Vaccine Production (bn doses): Forecast, 2020-2025 Table 4.4 Vaccine Production (bn doses) in Leading National Sectors, 2009 Table 4.5 Vaccine Production (bn doses) in Leading European Countries, 2009 Table 4.6 Vaccine Production (bn doses): Forecast by Leading National Markets, 2009-2015 Table 4.7 Manufacturing Facilities of Top 10 Vaccine Manufacturers, 2010 Table 4.8 Manufacturing Sites of Top 10 Vaccine Manufacturers: Location and Number in Europe, 2010 Table 4.9 Prominent Emerging Vaccine Manufacturers, 2010 Table 4.10 Development of Influenza Vaccine Production in Developing Countries, 2010 Table 5.1 Vaccines Contract Manufacturing Market Revenues ($m), 2009 Table 5.2 Vaccines Contract Manufacturing Market Revenue ($m) Forecast, 2009-2015 Table 5.3 Vaccines Contract Manufacturing Market Revenue ($m) Forecast, 2016-2025 Table 5.4 Some Outsourcing Deals In the Vaccine Manufacturing Space Table 5.5 Prominent Contract Manufacturing Organisations Offering Vaccine Manufacturing, 2010 Table 5.6 Meridian Life Science Revenue ($m), 2008 and 2009 Table 6.1 Cell-Culture Based Vaccine Manufacturing Technologies and Product Developments, 2010 Table 6.2 Commercial Licensing Deals for Vivalis' EB66 Cell Technology Table 6.3 Licensing Deals for ProBioGen AG's AGE1.CR Cell Technology Table 6.4 Vaccine Development Pipeline using Medicago's Proficia VLP Vaccine Technology, 2010 Table 6.5 Vaccine Development Pipeline using iBio's iBioLaunch Vaccine Technology, 2010 Table 6.6 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2010 Table 6.7 Vaccine Development Pipeline using Crucell's AdVac Technology, 2010 Table 6.8 Benefits and Drawbacks of using Disposable Technology for Vaccine Production, 2010 Table 6.9 Companies Providing Disposable Biomanufacturing Platforms/ Systems, 2010 Table 7.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2010 Figure 3.1 Vaccine Market Shares (%) by Type, 2009 Figure 3.2 Vaccine Market Shares (%) by Brand, 2009 Figure 3.3 Vaccine Market Shares (%) by Manufacturer, 2009 Figure 3.4 Global Vaccine Market Forecast ($bn), 2010-2025 Figure 3.5 Global Vaccine Market Shares (%) by Vaccine Type, 2010 Figure 3.6 Global Vaccine Market Shares (%) by Vaccine Type, 2015 Figure 3.7 Global Vaccine Market Shares (%) by Vaccine Type, 2020 Figure 3.8 Global Vaccine Market Shares (%) by Vaccine Type, 2025 Figure 4.1 Shares (%) of Global Vaccine Production by Volume, 2009 Figure 4.2 Global Vaccine Production (bn doses): Forecast, 2009-2025 Figure 4.3 Regional Shares (%) of Global Vaccine Production, 2009 Figure 4.4 Vaccine Production Shares (%) by Leading European Countries, 2009 Figure 4.5 Regional Shares (%) of Global Vaccine Production, 2010 Figure 4.6 Regional Shares (%) of Global Vaccine Production, 2015 Figure 4.7 Regional Shares (%) of Global Vaccine Production, 2020 Figure 4.8 Regional Shares (%) of Global Vaccine Production, 2025 Figure 4.9 Regional Shares (%) of Manufacturing Facilities of Top 10 Vaccine Manufacturers, 2010 Figure 5.1 Market Shares (%) of Vaccines in Biologics Contract Manufacturing, 2009 Figure 5.2 Vaccines Contract Manufacturing Market Revenue ($m) Forecast, 2009-2025 Figure 5.3 Revenue Share (%) of Meridian Life Science in Meridian Bioscience Revenues, 2009 Figure 6.1 Steps in Vaccine Production, 2010 Figure 6.2 Egg-Based Production Process for Viral Vaccines, 2010 Figure 6.3 Influenza Vaccine Production Using Cell-Based Manufacturing Method, 2010 Figure 6.4 Novavax' Insect Egg-Based Vaccine Production Process, 2010 Figure 9.1 Comparison of Vaccine Manufacturing Capabilities of Different Organisation Types, 2010 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
